Related Experiment Video
Updated: Jul 28, 2025

Intra-lymph Node Injection of Biodegradable Polymer Particles
Published on: January 2, 2014
Recent advances in lipid-based long-acting injectable depot formulations
Reena Sharma1, Sheetal Yadav1, Vivek Yadav1
1Department of Pharmaceutics, Centre for Pharmaceutical Nanotechnology, National Institute of Pharmaceutical Education & Research (NIPER), Sector 67, S.A.S. Nagar (Mohali), Punjab 160062, India.
Long-acting injectable (LAI) systems using lipid depots offer sustained drug delivery, reducing dosage frequency and improving patient compliance for chronic diseases. This review highlights advancements, market availability, and challenges in developing these innovative lipid-based LAIs.
Area of Science:
- Pharmaceutical Sciences
- Biomaterials Engineering
- Drug Delivery Systems
Background:
- Long-acting injectables (LAIs) enhance therapeutic outcomes by providing sustained drug release.
- Lipid-based depots are biocompatible and improve drug stability for chronic disease management.
- Existing LAI formulations include oil solutions, liposomes, and lipid nanoparticles.
Purpose of the Study:
- To review recent advancements in lipid-based LAIs for small and macromolecules.
- To discuss the potential of lipid-based LAIs in managing chronic diseases.
- To provide an overview of available lipid depots, patents, and challenges in LAI development.
Main Methods:
- Comprehensive literature review of scientific databases and patent repositories.
- Analysis of lipid depot formulations, including oil solutions, oleogels, liposomes, and lipid nanoparticles.
- Critical discussion on in vitro release methods and in vitro-in vivo correlation (IVIVC).
Main Results:
- Lipid-based LAIs show significant promise for treating chronic conditions like psychosis, diabetes, and cancer.
- Various lipid depot types are available, with some in clinical phases and protected by patents.
- In vitro release studies are crucial but challenging for establishing reliable IVIVC.
Conclusions:
- Lipid-based LAIs represent a significant advancement in drug delivery for chronic diseases.
- Further research is needed to overcome challenges in developing and validating these systems.
- Successful development of lipid-based LAIs can improve patient compliance and therapeutic efficacy.
More Related Videos
Related Concept Videos
Insulin Formulations: Types and Delivery
Short-acting insulins are divided into...
Drug Delivery: Miscellaneous Routes
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
Drug Delivery: Parenteral Route
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
Drug Delivery: Overview
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the...
Routes of Drug Administration: Parenteral
The intravenous route (IV) of drug administration can be further categorized into two types. The bolus injection administers the entire dose rapidly, while an intravenous infusion slowly delivers smaller doses steadily.
The IV route is often...
Biopharmaceutics and Pharmacokinetics: Overview

